Sun Pharmaceutical Industries, the largest pharma company in India, announced the start of a US website for its long-term care (LTC) division, www.sunltc.com.
The website has the LTC portfolio of alternative formulation products and hopes to meet the needs of nearly 40% of American adults who cannot or will not swallow solid medication forms, according to a statement.
The LTC portfolio includes the first and only US Food and Drug Administration-approved extended-release sprinkle formulation of metoprolol succinate, sprinkle formulation of delayed-release duloxetine, and sprinkle formulation of rosuvastatin.
The Ezallor Sprinkle (rosuvastatin) immediate-release capsule label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.
Quality supplier
The Indian pharmaceutical industry has developed itself as a reliable, high-quality, and cost-effective global drug supplier, according to a McKinsey report. By making essential drugs affordable and accessible, it has captured a leading share in developed economies such as the US (1 of every 3 pills) and the United Kingdom (25 percent of medicines consumed).
The industry is worth over $38 billion and may grow between $120 to 130 billion by 2030, the report stated.
Sun Pharmaceuticals offers formulations in various therapeutic areas, such as diabetology, cardiology, neurology, gastroenterology, and psychiatry. It provides APIs such as etodolac, warfarin and clorazepate. The Mumbai-headquartered firm earned more than 50% of its revenue from the US market in the fiscal ending March 31, 2020.
